Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan

Executive Summary

FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.
Advertisement

Related Content

At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
FDA Should Drop Ban On Office Compounding, US House Members Say
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
FDA Commissioner Outlines Priorities For Tightening Oversight Of Drug Compounding Facilities
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Drug Compounding Can't Be Justified By Price, FDA Says
FDA Making A Generic Case For Continuous Manufacturing
FDA Talks Up Continuous Manufacturing, Offers Assistance

Topics

Advertisement
UsernamePublicRestriction

Register

PS122513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel